Cassia senna

Related Terms

Aden senna, Agiocur?, Agiolax?, Alexandrian senna, Alexandrinische Senna (German), barakol, casse, Cassia acutifolia, Cassia alata, Cassia angustifolia, Cassia marilandica, Cassia obtusifolia L., Cassia senna, Cassia tora L., Cassiae senna, cassine, dianthrones, extractum Sennae, Fletcher's Castoria?, Glysennid?, hairy roots, Indian senna, Khartoum senna, locust plant, Lunelax?, Mecca senna, Nubian senna, Perdiem, Prunasine?, Pursennid?, rhein, rhein 8-O-glucoside, rheinanthrone, sena alejandrina (Spanish), s?n? d'Egypte (French), Senna alata (L.) Roxb. (Fabaceae), Senna alexandrina spp., Senna didymobotrya (Fresen.) H.S.Irwin & Barneby, senna fruit, Senna obtusifolia (L.), Senna occidentalis (L.) Link (Fabaceae), senna pods, Senna racemosa, Senna spectabilis, Senna tora (L.) Roxb., Sennae folium, Sennae fructus, Sennatin?, sennidine monoglycosides, sennoside A, sennoside B, Senokot?, SofsenaT, Tinnevelly senna fruits, true senna, winged senna, X-prep?.

Background

The leaves or pods of the senna plant (Cassia senna) have been used by Arab physicians for their laxative properties since at least the ninth Century. Today, senna is a U.S. Food and Drug Administration (FDA)-approved nonprescription drug and an ingredient in several commercial laxatives.
There are over 400 known species of Cassia. Both the leaves and the seedpods (fruit) have laxative activity, due to the presence of compounds called anthraquinones. These compounds found in senna are also found in other plants with laxative properties, including cascara (Cascara sagrada), rhubarb (Rheum spp.), and aloe (Aloe vera). Senna accelerates defecation, in contrast to softening the stools, as some laxatives do. When taken at much higher than recommended doses or when used for the long term (laxative abuse), adverse effects, such as low blood potassium, may occur.
Some evidence supports the use of senna in adults for the treatment of chronic constipation or constipation induced by childbirth or drugs. In children, the available evidence suggests that mineral oil and lactulose may be safer and more effective than senna for treating chronic constipation. Some experts believe that senna is a more acceptable laxative than cascara or aloe for drug-induced constipation. Approximately 80% of terminal cancer patients who are taking opioids for pain relief require laxatives. Some evidence suggests that senna may be as effective and safe as lactulose for these patients.

Evidence Table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *


The available evidence suggests that mineral oil and lactulose may be safer and more effective laxatives than senna for treating children with chronic constipation. Further research is required before conclusions may be made.

 C


The available evidence suggests that mineral oil and lactulose may be safer and more effective laxatives than senna for treating children with chronic constipation. Further research is required before conclusions may be made.

 C


Although senna is commonly used to reduce constipation, the available clinical research is mixed. Some studies have shown that senna may be more effective than some other laxatives and have fewer side effects. Further trials are needed before a conclusion may be made.

 C


Although senna is commonly used to reduce constipation, the available clinical research is mixed. Some studies have shown that senna may be more effective than some other laxatives and have fewer side effects. Further trials are needed before a conclusion may be made.

 C


Some evidence supports the use of senna as an adjunct therapy in the treatment of cancer patients who have constipation as a result of taking opioids for pain. Further research should assess the length of time such patients may safely use senna.

 C


Some evidence supports the use of senna as an adjunct therapy in the treatment of cancer patients who have constipation as a result of taking opioids for pain. Further research should assess the length of time such patients may safely use senna.

 C


Senna has been examined as a potential treatment for postoperative constipation. Additional research is needed before a conclusion may be made.

 C


Senna has been examined as a potential treatment for postoperative constipation. Additional research is needed before a conclusion may be made.

 C


Senna has been examined as a method for preparing the bowel before diagnostic procedures that require clear visualization of the abdominal area. Further studies are needed in this area.

 C


Senna has been examined as a method for preparing the bowel before diagnostic procedures that require clear visualization of the abdominal area. Further studies are needed in this area.

 C


Data on the use of senna for cleaning the colon in preparation for colonoscopy are mixed. Some adverse effects have been reported with this use. Additional research is needed before a conclusion can be made.

 C


Data on the use of senna for cleaning the colon in preparation for colonoscopy are mixed. Some adverse effects have been reported with this use. Additional research is needed before a conclusion can be made.

 C
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)

Tradition / Theory

The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.

Dosing

Adults (18 years and older)
Doses must be determined for each patient, due to individual variability. A tea may be made from dried senna leaves or fruits.
For chronic constipation, 1-2 tablets (or one teaspoon) of Senokot? have been taken daily by mouth. One to two tablets of Senokot-S?, increasing to a maximum of three tablets twice daily, or reducing to one tablet daily or every other day, have been taken by mouth in a nursing home setting. A dose of 14.8 grams of Agiolax? (senna combined with a bulk laxative) has been taken by mouth daily in geriatric patients. Four tablets daily of Senokot?, given in divided doses in the morning and evening until a bowel movement occurs, or a maximum of 16 doses, have been taken by mouth for postpartum constipation. One teaspoon of senna granules, consisting of 450 milligrams of Cassia acutifolia pod, has been taken by mouth once daily after childbirth, followed by either one-half or one whole teaspoon of senna granules at bedtime. One teaspoon of water-soluble senna extract, standardized to 20 milligrams of sennosides, has been added to one cup of water and taken by mouth daily for at least six weeks. Glysennid? has been taken by mouth in an initial dose of one tablet nightly, increased (to a maximum of three tablets daily) or decreased (to a minimum of one tablet daily) according to individual response. Senna leaves or pods have been taken by mouth in doses of 0.6-2 grams daily, together with a dose of 20-30 milligrams of sennoside B.
For constipation (opioid-induced), half of a Senokot? concentrated senna tablet has been taken by mouth to counteract each 60 milligrams of codeine or its equivalent. Senna (starting with 0.4 milliliters daily) has been taken by mouth for 27 days.
For constipation (postoperative), 1-2 tablets (one teaspoon) of senna (Senokot?) has been taken by mouth as a single dose.
For a laxative or bowel preparation for procedures, senna (one package diluted in a glass of water) has been taken by mouth the evening before surgery. Two tablets of Senokot? DX (14 milligrams of sennosides A and B) have been taken by mouth on the two evenings before X-ray examination. A dose of one milliliter per kilogram of body weight (to a maximum of 75 milliliters) of a syrup containing 2.0 milligrams of sennoside A and B per milliliter (X-prep?) has been taken by mouth. A dose of one milliliter per kilogram of body weight of Prunasine? (to a maximum dose of 75 milliliters) has been taken by mouth. A dose of 180 milligrams of senna has been taken by mouth one day prior to colonoscopy. A dose of 75 milliliters of a senna laxative has also been taken by mouth the day before colonoscopy. Twenty-four tablets of 12 milligrams senna have been divided into two doses and taken by mouth.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Interactions

Interactions with Drugs
Although the effect has not been well studied in humans, senna may decrease the absorption of some drugs, due to the presence of anthranoid compounds.
Senna may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants (blood thinners) such as warfarin (Coumadin?) or heparin, antiplatelet drugs such as clopidogrel (Plavix?), and nonsteroidal anti-inflammatory drugs such as ibuprofen (Motrin?, Advil?) or naproxen (Naprosyn?, Aleve?).
Senna may also interact with antibiotics, anticancer agents, antivenom agents, antiviral agents, digoxin, diuretics, hormonal agents, or laxatives.

Attribution

This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).

Bibliography

Fingerhut A, Hay JM. Single-dose ceftriaxone, ornidazole, and povidone-iodine enema in elective left colectomy. A randomized multicenter controlled trial. The French Association for Surgical Research Arch Surg 1993;128(2):228-232.
Fournier AM. [Use of senna for the acceleration of small intestine transit in hospital radiology]. Mars Med 1971;108(6):469-474.
Glatzel, H. [Senna--an old drug in a new form]. Z Allgemeinmed 1970;46(2):82-84.
Godding EW. Laxatives and the special role of senna. Pharmacology 1988;36 Suppl 1:230-236.
Han RX. [Study of the cleansing effect of senna on the intestinal tract]. Zhonghua Hu Li Za Zhi 1989;24(5):273-275.
Heaton KW, Cripps HA. Straining at stool and laxative taking in an English population. Dig Dis Sci 1993;38(6):1004-1008.
Langmead L, Rampton DS. Review article: herbal treatment in gastrointestinal and liver disease--benefits and dangers. Aliment Pharmacol Ther 2001;15(9):1239-1252.
Mishalany H. Seven years' experience with idiopathic unremitting chronic constipation. J Pediatr Surg 1989;24(4):360-362.
Monias MB. Standardized senna concentrate in postpartum bowel rehabilitation. Md State Med J 1966;15(2):32-33.
No authors listed. Senna and habituation. Pharmacology 1992;44 Suppl 1:30-32.
Pahor M, Mugelli A, Guralnik JM, et al. Age and laxative use in hospitalized patients. A report of the "Gruppo Italiano di Farmacovigilanza nell'Anziano--GIFA". Aging (Milano) 1995;7(2):128-135.
Senna in the puerperium. Pharmacology 1992;44 Suppl 1:23-25.
Tooson JD, Gates LK, Jr. Bowel preparation before colonoscopy. Choosing the best lavage regimen. Postgrad Med 1996;100(2):203-12, 214.
Vaidyanathan S, Soni BM. Bluish discolouration of urine drainage tube and bag in a female patient with spina bifida, paraplegia, and suprapubic cystostomy. ScientificWorldJournal 2007;7:1070-1072.
Valverde A, Msika S, Kianmanesh R, et al. Povidone-iodine vs sodium hypochlorite enema for mechanical preparation before elective open colonic or rectal resection with primary anastomosis: a multicenter randomized controlled trial. Arch Surg 2006;141(12):1168-1174.